How they work

How Does Zepbound Work? GIP and GLP-1 Explained

Zepbound is tirzepatide, the same molecule as Mounjaro, approved for weight management and sleep apnea. It activates two gut hormone receptors - GIP and GLP-1 - and this guide explains what each one does to appetite, fat tissue and the brain.

Last verified September 14, 2026·13 sources cited·Ozempic Wegovy Zepbound

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

Zepbound is the brand name for tirzepatide when it is prescribed for weight. The FDA approved it in November 2023 for chronic weight management and added obstructive sleep apnea in December 2024. The current label, revised in August 2026, describes it as “a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist” used alongside a reduced-calorie diet and increased physical activity [1].

That opening phrase is the whole story compressed. Zepbound works on two hormone systems. Most people have heard of one of them. This article explains both, and what each one is doing while you take the drug.

None of this is medical advice. Whether Zepbound is appropriate for a particular person, and at what dose, is a decision for a healthcare provider.

What are GIP and GLP-1?

They are incretins - hormones your gut releases when food arrives, before your blood sugar has even had time to climb much. Their job is to tell the pancreas that fuel is coming.

GLP-1 (glucagon-like peptide-1) comes from L-cells in the lower small intestine and colon. It raises insulin when glucose is high, suppresses glucagon (the hormone that tells the liver to release stored sugar), slows the stomach, and reduces appetite by acting on the brain.

GIP (glucose-dependent insulinotropic polypeptide) comes from K-cells higher up, in the duodenum and upper small intestine. It was actually discovered first. It raises insulin when glucose is high, but it does not suppress glucagon. It responds strongly to fatty meals and helps direct incoming fat and sugar into storage [2].

Both are destroyed within a couple of minutes by an enzyme called DPP-4. That is why neither hormone works as a drug on its own, and why every incretin medicine is engineered to resist that enzyme.

What does tirzepatide do differently?

Tirzepatide is a 39-amino-acid peptide built on the human GIP sequence. Lilly’s scientists took GIP and engineered GLP-1 activity into it, rather than the other way around [3]. Two positions carry a non-natural amino acid called alpha-aminoisobutyric acid, which blocks the DPP-4 cut site. A 20-carbon fatty acid chain hangs off lysine 20, letting the molecule grip albumin in the blood so it lasts about five days instead of five minutes [1].

Semaglutide - the molecule in Wegovy and Ozempic - is 31 amino acids, built on GLP-1, and hits one receptor. Tirzepatide is longer, built on GIP, and hits two. They are genuinely different drugs, not two strengths of the same idea.

What is the GLP-1 half of Zepbound doing?

This is the familiar part.

It reduces appetite through the brain. GLP-1 receptors sit in the hypothalamus and the brainstem, and activating them reduces how much food feels appealing and how much it takes to feel full. The Zepbound label states: “Tirzepatide decreases calorie intake. The effects are likely mediated by affecting appetite” [1]. A 2026 post hoc analysis of the SURMOUNT trials cites model-estimated reductions in daily energy intake as large as 1,200 calories per day for both semaglutide and tirzepatide - an estimate from modeling, not a direct measurement [4].

It slows the stomach, temporarily. Food sits longer, which contributes to fullness early in treatment. The label is explicit about the fade: “Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time” [1]. Using acetaminophen as a marker, a first 5 mg dose cut peak acetaminophen levels by 55 percent and delayed the peak by an hour. By week six at 15 mg, there was no meaningful effect left [1].

It manages blood sugar. Even in people without diabetes, the label notes tirzepatide stimulates insulin secretion in a glucose-dependent way, reduces glucagon, and improves insulin sensitivity [1].

What is the GIP half doing?

This is the part that makes tirzepatide unusual, and the part where the honest answer is “we have good hypotheses and mostly animal evidence.”

GIP receptors are on fat cells. GLP-1 receptors are not.

This is the cleanest structural difference between the two drugs. Fat tissue expresses GIP receptors and does not express GLP-1 receptors, which means tirzepatide can talk to fat cells directly and semaglutide cannot.

Lilly’s own laboratory work, published in Cell Metabolism in 2024, describes what happens. When insulin is present - the fed state - GIP receptor activation enhances insulin signaling in fat cells, increases glucose uptake, and helps convert glucose to glycerol. When insulin is low - the fasted state - the same GIP receptor activation increases lipolysis, pushing stored fat back out. In obese mice, a long-acting GIP receptor agonist lowered circulating triglycerides after a fat meal and increased fat uptake into adipose tissue [5].

The authors frame it as nutrient partitioning: helping fat tissue do its buffering job better in both directions. That is a laboratory and rodent finding, not something measured in people on Zepbound.

GIP receptors are in a different part of the appetite brain

Both incretin receptors appear in appetite-controlling brain regions, but on different neurons. In mice, GIP receptor agonists reduce food intake through GABAergic neurons; GLP-1 receptor agonists work through glutamatergic ones [6]. Two separate levers, not one lever pushed harder.

Mice engineered without brain GIP receptors are protected from diet-induced obesity, and in those animals a GLP-1/GIP dual agonist loses its advantage over a GLP-1 agonist alone [7]. In 2026, researchers narrowed the location: deleting the GIP receptor specifically in the area postrema, a small region of the brainstem, abolished the appetite-suppressing effect of a GIP agonist [8].

GIP may make the GLP-1 part easier to tolerate

GIP is anti-emetic in animal models - it reduces nausea-related behavior triggered by several different agents [6].

A small Phase 1 crossover study tested this directly in 32 healthy volunteers. Participants were put through a deliberately rapid liraglutide escalation designed to provoke gut symptoms, once with placebo pretreatment and once with a single dose of a long-acting selective GIP receptor agonist. Total gastrointestinal side effects fell from 75 to 41 (P = 0.022). Reflux events fell from 14 to 5 [9].

That is a small study of a different molecule in healthy people. Zepbound’s own label lists nausea, diarrhea, vomiting, constipation and abdominal pain among the reactions reported in at least 5 percent of patients [1]. The GIP tolerability idea explains why the dual agonist might be pushed to higher effective exposure, not why side effects disappear.

Is the GIP receptor being turned up or turned off?

Here is the genuinely strange part of this field, and it is worth knowing because competing drugs take opposite approaches.

Tirzepatide activates the GIP receptor. Amgen’s MariTide blocks it. Both, when combined with GLP-1 receptor activation, produce more weight loss than GLP-1 activation alone [10]. Researchers call this the GIP paradox.

Several explanations are in play:

Different brain circuits. A 2026 Nature Metabolism study found that GIP receptors in the area postrema drive the appetite effect of agonists, while GIP receptors in the hypothalamus drive the extra weight loss from antagonists added to GLP-1 or amylin drugs [8].
Antagonism unlocks GLP-1. A 2025 study found the weight effects of GIP receptor blockade disappear in mice lacking the GLP-1 receptor, and that blockade - not activation - mimics the gene-expression signature of GLP-1 receptor activation in the hindbrain [11].
Chronic activation looks like blockade. Some researchers argue that constantly stimulating the GIP receptor desensitizes it so much that it ends up functionally switched off. A 2025 point-counterpoint in Diabetes concluded the evidence for that in appetite neurons is not there yet [12].

This lane presents the paradox as unresolved, because it is. For a consumer, the practical point is that both strategies are in clinical development and neither has been shown to be better.

Is the imbalance between the two receptors deliberate?

Yes, and it matters. Tirzepatide does not treat its two targets equally.

It binds the GIP receptor about as tightly as your own GIP does. It binds the GLP-1 receptor roughly five times more weakly than your own GLP-1 does [3]. Researchers call it an “imbalanced” dual agonist, tilted toward GIP.

The argument for building it that way is straightforward. GLP-1 receptor activation is what limits dose escalation through nausea and vomiting. GIP receptor activation is not known to cause the same problem. So a molecule that leans on GIP can be dosed to higher total exposure before the gut complains [13].

There is a second layer. When tirzepatide activates the GLP-1 receptor, it produces cyclic AMP but recruits very little beta-arrestin - the protein that normally drags a receptor off the cell surface after use. Less beta-arrestin may mean less receptor shutdown. FDA’s own clinical pharmacology review describes tirzepatide as “a biased agonist” at the GLP-1 receptor on exactly these grounds [13][14]. Whether that translates into any clinical advantage is still debated; some mouse studies support it and at least one does not.

What does the weight loss actually consist of?

A substudy of SURMOUNT-1 measured body composition with DXA scans in 160 participants at baseline and week 72 [15].

Body weight: down 21.3 percent with tirzepatide, 5.3 percent with placebo
Fat mass: down 33.9 percent versus 8.2 percent
Lean mass: down 10.9 percent versus 2.6 percent
Visceral fat mass: down 40.1 percent versus 7.3 percent
Waist circumference: down 18.1 cm versus 3.4 cm

In absolute terms, tirzepatide participants lost 15.9 kg of fat and 5.6 kg of lean mass. About 74 percent of the weight lost was fat and about 26 percent was lean - essentially the same proportion as in the placebo group, which lost far less overall [15]. The Zepbound label states it more simply: “Tirzepatide lowers body weight with greater fat mass loss than lean mass loss” [1].

Two caveats. The substudy is small - 160 of 2,539 participants. And DXA “lean mass” includes water and organs, not just muscle, so it is not a precise muscle measurement.

What happens if the dose comes down?

SURMOUNT-MAINTAIN, published in The Lancet in May 2026, is the first randomized trial to test that question [16].

441 adults took open-label tirzepatide at their maximum tolerated dose (10 or 15 mg) for 60 weeks. The 378 who lost at least 5 percent and tolerated at least 10 mg were then randomized to stay at the maximum tolerated dose, drop to 5 mg, or switch to placebo for another 52 weeks.

At week 112, weight change from the original baseline was -21.9 percent for the maximum tolerated dose group, -16.6 percent for the 5 mg group, and -9.9 percent for placebo. Rescue tirzepatide, which the trial offered from week 84 to anyone who had regained at least half the weight they lost, was received by 8 percent of the maximum-dose group, 25 percent of the 5 mg group, and 67 percent of the placebo group [16][17].

That is trial evidence about what different dose strategies do. It is not advice, and dose changes belong with a prescriber.

How is Zepbound taken?

Once weekly, subcutaneously, any time of day, with or without meals, rotating between abdomen, thigh and the back of the upper arm. The label starts at 2.5 mg weekly for four weeks, then 5 mg, with further 2.5 mg increases no sooner than every four weeks. Maintenance is 5, 10 or 15 mg for weight reduction and 10 or 15 mg for obstructive sleep apnea. The maximum for all indications is 15 mg [1].

The label is specific that “the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage,” and that the escalation exists to reduce gastrointestinal side effects. It also tells prescribers to consider a lower maintenance dose if a patient cannot tolerate the current one [1].

Since February 2026, Zepbound has been available in a four-dose KwikPen as well as single-dose pens and vials, with all six strengths available in either format [18].

The bottom line

Zepbound works through two hormone receptors instead of one. The GLP-1 receptor handles appetite through one set of brain neurons, temporarily slows the stomach, and manages blood sugar. The GIP receptor adds a second appetite pathway through a different brain region, reaches fat cells that GLP-1 receptors never touch, and may take some of the edge off nausea.

Whether that combination is why tirzepatide outperformed semaglutide in head-to-head trials is a question the field has not closed. What is settled is that they are different molecules with different targets, different half-lives and separate labels - and that any decision about using either belongs with a healthcare provider.

Sources

Questions people ask

What is the difference between GIP and GLP-1?

Both are incretin hormones released by the gut after you eat, and both tell the pancreas to release insulin when blood sugar is high. GLP-1 also suppresses glucagon, slows the stomach and reduces appetite through the brain. GIP does not suppress glucagon, but it acts on fat cells (which GLP-1 receptors do not reach), works through a different set of appetite neurons, and appears to reduce nausea in animal studies.

Is Zepbound the same as Mounjaro?

The active ingredient is identical: tirzepatide, in the same six strengths. The difference is the FDA-approved use. Zepbound covers weight management and obstructive sleep apnea; Mounjaro covers type 2 diabetes and cardiovascular risk reduction. Zepbound's label says not to take it with other tirzepatide products or with any GLP-1 receptor agonist.

How does Zepbound reduce appetite?

The label says simply that 'Tirzepatide decreases calorie intake' and that 'the effects are likely mediated by affecting appetite.' The mechanism involves GLP-1 receptors on one set of brain neurons and GIP receptors on a different set, plus a temporary slowing of the stomach that fades over the first several weeks.

Does Zepbound burn fat or just reduce eating?

Mostly it reduces how much you eat. In the SURMOUNT-1 body composition substudy, about 74 percent of the weight lost was fat mass and about 26 percent was lean mass - almost exactly the same split seen in the placebo group. Visceral fat fell 40 percent. Laboratory work suggests GIP receptor activation also changes how fat cells handle nutrients, but that has not been measured directly in people.

Why does Zepbound come in two maintenance dose ranges?

The label sets maintenance at 5, 10 or 15 mg weekly for weight reduction, but 10 or 15 mg for obstructive sleep apnea. The 2.5 mg dose is described in the label as for treatment initiation only and is not approved as a maintenance dose for either indication.

Does Zepbound stop working over time?

One specific effect does fade: the gastric emptying delay. The label says it is largest after the first dose and diminishes over time. The appetite and weight effects behave differently. In SURMOUNT-MAINTAIN, people who stayed on their maximum tolerated dose for a second year kept essentially all their weight loss, while those switched to placebo regained a large share of it.

Is the GIP part what makes tirzepatide work better than semaglutide?

That is the leading hypothesis, but it has not been proven. Tirzepatide beat semaglutide 2.4 mg on weight in the head-to-head SURMOUNT-5 trial. Whether the extra effect comes from GIP receptor activation, from biased signaling at the GLP-1 receptor, from the higher milligram doses used, or from some mix, is still being worked out.

Does activating GIP cause weight gain?

That was the old worry, because GIP promotes fat storage after meals. But both activating and blocking the GIP receptor add to weight loss when combined with GLP-1 activation, which researchers call the GIP paradox. A 2026 study suggests they work through different brain regions - the area postrema for activation, the hypothalamus for blockade.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.